Parkwalk exited Horizon Discovery in May 2017 having invested in May 2013. The exit generated a 2.36x return (3.37x inclusive of initial tax reliefs) for our investors.

Having invested in a private funding round, Horizon had a successful IPO in March 2014, raising £40m to list with a market capitalisation of £120m. 

Horizon’s basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.

Horizon aspires to provide solutions that unlock the promise of the human genome project for the benefit of scientific researchers, patients and society; provide powerful research tools to advance the development of personalized medicines; provide molecular reference standards and support better healthcare outcomes for patients.